Jeff Quillen Discusses Major Life Sciences Deals & Trends of 2025

TL/DR –

Jeff Quillen, partner and co-chair of Foley Hoag’s Life Sciences Industry Group, highlighted the significant developments in healthcare dealmaking in 2025 in two recent Law360 articles. He emphasized the importance of Eli Lilly’s acquisitions of Verve Therapeutics and Adverum, and Pfizer’s $10 billion acquisition of Metsera in the field of gene therapy and metabolic obesity. Quillen also discussed the rise of Chinese biotechs as a major player in global dealmaking and the positive impact of the NASDAQ Biotech Index increasing by over 30% since the start of the year on investor sentiment and deal activity.

Jeff Quillen’s Analysis on Key Developments in Healthcare and Life Sciences Deals

Jeff Quillen, esteemed partner at Foley Hoag’s Life Sciences Industry Group, recently provided insight into the top developments in healthcare and life sciences dealmaking in 2025. His input formed the basis of two Law360 articles.

Eli Lilly’s Investments in Gene Therapy

In the article, “The Most Important Healthcare and Life Science Deals of 2025,” Quillen emphasized Eli Lilly’s acquisitions of Verve Therapeutics and Adverum. Both deals, which happened in June and October respectively, are advancing the field of gene therapy. Despite the fluctuating interest from investors, Lilly’s successful metabolic obesity programs have rekindled the gene therapy spotlight. Quillen also highlighted Pfizer’s $10 billion acquisition of Metsera, another significant move that indicates the growing opportunities in the metabolic obesity segment.

Rise of Chinese Biotech Firms in Global Dealmaking

The second article, “Trends That Shaped Healthcare Dealmaking in 2025“, saw Quillen commenting on the growing influence of Chinese biotechs in global dealmaking. As China evolves into a biotech innovation hub, U.S-based biotechs who are planning to sell or license novel products to big pharma must be aware of this new competitor.

Positive Growth of NASDAQ Biotech Index

Lastly, Quillen acknowledged the consistent growth of the NASDAQ Biotech Index, which increased by over 30% since the beginning of the year. Such growth is seen as a positive indication for both investors and companies, potentially leading to a surge in deal activities.

—
Read More Health & Wellness News ; US News